Updates, milestones, and links shared by Saku Biosciences.
Established a partnership with Growth Curve Bio (GCB), demonstrating strong demand from contract development manufacturing organizations (CDMOs) for integrated microbe engineering capabilities. This enables a full-stack offering from strain development through scale-up, improving customer outcomes and increasing deal flow.
Established a partnership with Research Triangle Institute (RTI) to combine Saku’s biological engineering capabilities with RTI’s chemical engineering expertise. This expands our scope beyond biomanufacturing to address broader challenges across chemical manufacturing and enables development of integrated, end-to-end production solutions.
Released first technical whitepaper demonstrating increased manufacturing output using our platform. Improved fatty acid production in two industrial yeast species by 31% and 47%. Achieved these results in 2 months and $10,000, compared to typical approaches that require 6+ months and $100,000. This validates our ability to rapidly improve production microbes while significantly reducing time and cost.
Secured a $200,000 DOE-funded CRADA with Lawrence Berkeley National Laboratory, Sandia National Laboratories, and ABPDU to enhance fermented fatty acid production as a replacement for palm oil. This provides third-party validation from leading federal labs and demonstrates early traction in sustainable, domestically produced alternatives to global commodity inputs.
Signed a $200,000 milestone-based contract with CyanoCapture to enhance insulin production. This represents early commercial validation of our platform in high-value therapeutics and demonstrates customer willingness to pay for improved manufacturing performance.